Introduction: Epilepsy is considered a chronic neurological condition that manifests itself with seizures, where 30% - 40% of patients do not achieve control of their seizures despite proper management. Seizures represent a significant limitation in the patient’s daily activities and are often accompanied by emotional and relational difficulties that have a great impact on the quality of life of the patient and their families. Cannabidiol (CBD) has been found to be effective in controlling seizures and may also improve cognitive and behavioral abilities. Material and Methods: The Quality of Life of the Patient with Epilepsy (CAVE) scale was applied to patients with refractory epilepsies who use Cannabidiol (CBD) added to their base therapy, before the use of CBD and after 12 months of follow-up. The presentation of collateral effects was also evaluated. Results: Out of 34 patients, 26 (76.5%) increased their CAVE value at the end of the study and only 1 (2.9%) decreased. 19 (55.9%) improved in learning and behavior, 55.8% in the frequency of seizures and 79.4% reported a decrease in the intensity of seizures. There were other positive side effects such as improvement in alertness, language, sleep and behavior. The main side effects were mild and transitory, including drowsiness, and constipation. There was a correlation between the global perception of improvement and seizure control. Conclusions: This study shows that in the long term CBD improves the quality of life of patients with refractory epilepsies, through the control of seizures and the improvement of cognitive and behavioral functions.
References
[1]
García-Galicia, A., García-Carrasco, M., Montiel-Jarquín, á.J., García-Cuautitla, M.A., Barragán-Hervella, R.G. and Romero-Figueroa, M.S. (2014) Validez y consistencia de las escalas ECAVIPEP y CAVE para evaluar la calidad de vida en pacientes pediátricos con epilepsia. Revista de Neurología 59, 301-306. https://doi.org/10.33588/rn.5907.2014241
[2]
Moya, J., Gómez, V. and Devilat, M. (2015) Calidad de Vida en Niños con Epilepsia Resistente. Revista Chilena De Epilepsia, 1, 12-25.
[3]
Puka, K. and Smith, M.L. (2015) Predictors of Long-Term Quality of Life after Pediatric Epilepsy Surgery. Epilepsia, 56, 873-881. https://doi.org/10.1111/epi.13004
[4]
Rosenberg, E.C., Louik, J., Conway, E., Devinsky, O. and Friedman, D. (2017) Quality of Life in Childhood Epilepsy in Pediatric Patients Enrolled in a Prospective, Open-Label Clinical Study with Cannabidiol. Epilepsia, 58, e96-e100. https://doi.org/10.1111/epi.13815
[5]
Cross, J.H., Devinsky, O., Laux, L., Marsh, E., Miller, I., Nabbout, R., et al. (2017) Cannabidiol (CBD) Reduces Convulsive Seizure Frequency in Dravet Syndrome: Results of a Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial (GWPCARE1). 32nd International Epilepsy Congress, Barcelona, Spain, 2-6 September 2017, 1-224.
[6]
Devinsky, O., Patel, A.D., Cross, J.H., Villanueva, V., Wirrell, E.C., Privitera, M., et al. (2018) Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. The New England Journal of Medicine, 378, 1888-1897. https://doi.org/10.1056/NEJMoa1714631
[7]
Pesántez Ríos, G., Armijos-Acurio, L., Jimbo-Sotomayor, R., Pascual-Pascual, S.I. and Pesántez-Cuesta, G. (2017) Cannabidiol: Its Use in Refractory Epilepsies. Revista de Neurología, 65, 157-160. https://doi.org/10.33588/rn.6504.2016573
[8]
Sheikh, S., Thompson, N., Bingaman, W., Gonzalez-Martinez, J., Najm, I. and Jehi, L. (2019) (Re)Defining Success in Epilepsy Surgery: The Importance of Relative Seizure Reduction in Patient-Reported Quality of Life. Epilepsia, 60, 2078-2085. https://doi.org/10.1111/epi.16327
[9]
Baca, C.B., Pieters, H.C., Iwaki, T.J., Mathern, G.W. and Vickrey, B.G. (2015) A Journey around the World: Parent Narratives of the Journey to Pediatric Resective Epilepsy Surgery and Beyond. Epilepsia, 56, 822-832. https://doi.org/10.1111/epi.12988
[10]
Law, N., Kerr, E. and Smith, M.L. (2015) Evaluation of Behavioral Outcomes in Children 1 Year after Epilepsy Surgery. Epilepsia, 56, 1605-1614. https://doi.org/10.1111/epi.13126
[11]
Koo, C.M., Kang, H. (2017) Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy? Journal of Epilepsy Research, 7, 16-20. https://doi.org/10.14581/jer.17003
[12]
Wilmshurst, J.M., Gaillard, W.D., Vinayan, K.P., Tsuchida, T.N., Plouin, P., Van Bogaert, P., et al. (2015) Summary of Recommendations for the Management of Infantile Seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia, 56, 1185-1197. https://doi.org/10.1111/epi.13057
[13]
Pesantez Ríos, G., Jimbo Sotomayor, R., Sánchez Choez, X., Valencia, C., Curatolo, P. and Pesantez Cuesta, G. (2018) Tuberous Sclerosis in Ecuador. Case Series Report. Neurología Argentina, 10, 66-71. https://doi.org/10.1016/j.neuarg.2017.10.002
[14]
Cilio, M.R., Thiele, E.A. and Devinsky, O. (2014) The Case for Assessing Cannabidiol in Epilepsy. Epilepsia, 55, 787-790. https://doi.org/10.1111/epi.12635
[15]
Porter, B.E. and Jacobson, C. (2013) Report of a Parent Survey of Cannabidiol-Enriched Cannabis Use in Pediatric Treatment-Resistant Epilepsy. Epilepsy & Behavior, 29, 574-577. https://doi.org/10.1016/j.yebeh.2013.08.037
[16]
Lagae, L. (2020) Long-Term Effects of Cannabinoids on Development/Behaviour. Epileptic Disorders, 22, 33-37.
[17]
Anciones, C. and Gil-Nagel, A. (2020) Adverse Effects of Cannabinoids. Epileptic Disorders, 22, S29-S32.
